机译:ObInutuzumab在先前未经处理的滤泡淋巴瘤患者中的功效和安全性:在随机阶段III镓试验中招收日本患者的亚组分析
School of Medicine Tokai University;
National Cancer Center Hospital;
Aichi Cancer Center;
Kobe City Medical Center General Hospital;
The Cancer Institute Hospital;
Tohoku University Graduate School of Medicine;
Jichi Medical University;
Matsushita Memorial Hospital;
National Hospital Organization Kyushu Cancer Center;
Niigata Cancer Center Hospital;
National Cancer Center Hospital East;
Chiba Cancer Center;
Kyoto Prefectural University of Medicine;
Japanese Red Cross Nagoya Daini Hospital;
Kumamoto University Graduate School of Medicine;
Aomori Prefectural Central Hospital;
Hiroshima University Hospital;
Gunma University Graduate School of Medicine;
Toranomon Hospital;
National Hospital Organization Shikoku Cancer Center;
Shinshu University School of Medicine;
The Jikei University School of Medicine;
Nagoya City University Graduate School of Medical Sciences;
Hyogo Cancer Center;
Chugai Pharmaceutical Co. Ltd;
Chugai Pharmaceutical Co. Ltd;
School of Medicine Tokai University;
Obinutuzumab; Rituximab; Follicular lymphoma; Japan;
机译:ObInutuzumab在先前未经处理的滤泡淋巴瘤患者中的功效和安全性:在随机阶段III镓试验中招收日本患者的亚组分析
机译:基于obInutuzumab的诱导和维持延长了以前未经处理的卵泡淋巴瘤患者的无进展生存(PFS):随机阶段3镓研究的主要结果
机译:诱导结束时和在维持期间的最小残留疾病反应与先前未处理的滤泡淋巴瘤患者的obinutuzumab-或基于Rituximab的免疫化学疗法的III次镓研究的更新结果相关
机译:互补疗法通过移动技术对冰岛同日外科患者的影响焦虑,痛苦和自我疗效愈合中的报告:过程中的随机对照试验
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:Bitopertin在精神分裂症和主要阴性症状患者中的疗效和安全性:来自全球随机2期试验的日本患者的亚组分析
机译:在随机期III镓研究中以前未经治疗的滤泡淋巴瘤中的obInutuzumab或rituximab的免疫化疗法:化疗方案分析